Press Releases

 
Press Releases
  Date Title and Summary View
Dec 9, 2003
Monrovia, CA – December 9, 2003 – Xencor today announced that its Board of Directors has appointed Harry Stylli, Ph.D., to serve as its new Chief Executive Officer and President, and also as a director of the company, effective November 3, 2003. Bassil Dahiyat, Ph.D., Xencor’s CEO since its founding, will assume the new role of...
PDF
Dec 9, 2003
Monrovia, CA – December 9, 2003 – Xencor today announced that its Board of Directors has appointed Bassil Dahiyat, Ph.D., to serve as its new Chief Scientific Officer, effective November 3, 2003. Dr. Dahiyat, Xencor’s founding CEO, will step down as President and CEO and will remain a director of the company. He will report to ...
PDF
Sep 30, 2003
Monrovia, CA – September 30, 2003 – Xencor today announced the issuance of U.S. Patent No. 6,627,186, entitled “Nucleic Acids and Protein Variants of hG-CSF with Granulopoietic Activity“. The patent covers a wide range of hG-CSF variants, which were designed using Xencor’s proprietary Protein Design Automation (PDA)...
PDF
Sep 25, 2003
Monrovia, CA – September 26, 2003 – Xencor, a drug discovery company, today reported the creation of a new class of inhibitors of TNF alpha, a critical protein involved in inflammatory disease. Scientists from Xencor used Protein Design Automation (PDA) technology, Xencor’s proprietary structure-based engineering platform, to d...
PDF
Sep 23, 2003
Monrovia, Calif.–Sept. 23, 2003–Technology Review, MIT’s magazine of innovation, announced in its October issue that Bassil Dahiyat, Ph.D., President and Chief Executive Officer of Xencor, a drug discovery company, has been named to its 2003 list of the world’s 100 Top Young Innovators. The TR100, chosen by the editors of...
PDF
Sep 23, 2003
Burnaby, British Columbia, Canada and Monrovia, California, United States – Chromos Molecular Systems Inc. (“Chromos“ TSX: CHR) and Xencor announced today that they have entered into a non-exclusive research license agreement to develop cell lines that express Xencor’s monoclonal antibodies and other recombinant protein p...
PDF
Oct 9, 2002
Monrovia, CA – October 9, 2002 – Xencor today announced that it has been awarded a $2 million Advanced Technology Program grant from the National Institute of Standards and Technology to support the discovery of safer and more effective protein therapeutics. The three-year federal grant, titled “Rational Design of Non-immunogen...
PDF
Jun 17, 2002
(BW Healthwire)–June 17, 2002—Monrovia, CA – Xencor today announced that it has reached a major milestone in its research agreement with Syngenta’s (NYSE: SYT) Torrey Mesa Research Institute (TMRI). In just six months, half the time agreed upon, Xencor has created and delivered optimized protein candidates that will enabl...
PDF
Jun 4, 2002
(BW Healthwire)–June 04, 2002—Xencor’s Vice President, Discovery Technologies, Robert Pacifici, Ph.D., Presents at BIO 2002, June 10 at 10:30 a.m.-12:00 p.m. in room 701A. Monrovia, CA – Xencor, a drug discovery company focused on protein optimization and chemical genomics, today announced that Robert Pacifici, Ph...
PDF
May 29, 2002
Monrovia, CA – May 29, 2002 – Xencor, a drug discovery company, today reported results from two protein optimization programs on key pharmaceutical proteins, recombinant human growth hormone (hGH) and granulocyte-colony stimulating factor (G-CSF). Using its proprietary Protein Design AutomationTM (PDATM) technology, Xencor computatio...
PDF
Page: FirstPrevious ...
18
NextLast
Xencor © Copyright 2017